Generic placeholder image

Current Gene Therapy

Editor-in-Chief

ISSN (Print): 1566-5232
ISSN (Online): 1875-5631

Review Article

CRISPR/Cas System: A Powerful Strategy to Improve Monogenic Human Diseases as Therapeutic Delivery; Current Applications and Challenges

In Press, (this is not the final "Version of Record"). Available online 07 January, 2025
Author(s): Fatemeh Saberi, Zeinab Yousefi-Najafabadi, Forough Shams*, Zeinab Dehghan, Sepideh Ahmadi, Tayyebeh Pilehchi, Effat Noori, Zeinab Esmaeelzadeh, Maryam Bazgiri, Rezvan Mohammadi, Farzaneh Khani, Marzieh Sameni, Parisa Moradbeigi, Gholam Ali Kardar, Mohammad Salehi, Yong Teng and Vahid Jajarmi
Published on: 07 January, 2025

DOI: 10.2174/0115665232345516241119070150

Price: $95

TIMBC 2025
Abstract

The 5,000 to 8,000 monogenic diseases are inherited disorders leading to mutations in a single gene. These diseases usually appear in childhood and sometimes lead to morbidity or premature death. Although treatments for such diseases exist, gene therapy is considered an effective and targeted method and has been used in clinics for monogenic diseases since 1989. Monogenic diseases are good candidates for novel therapeutic technologies like gene editing approaches to repair gene mutations. Clustered regularly interspaced short palindromic repeats (CRISPR)-based systems, the pioneer and effective gene editing tool, are utilized for ex vivo and in vivo treatment of monogenic diseases. The current review provides an overview of recent therapeutic applications of CRISPR-based gene editing in monogenic diseases in in vivo and ex vivo models. Furthermore, this review consolidates strategies aimed at providing new treatment options with gene therapy, thereby serving as a valuable reference for advancing the treatment landscape for patients with monogenic disorders.

Keywords: CRISPR/Cas system, gene therapy, gene editing, In vivo models, ex vivo models, monogenic diseases.


Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy